Concetta Di Nora1, Ugolino Livi1,2. 1. Department of Cardiothoracic Science. 2. Department of Medical Area (DAME), University of Udine, Udine, Italy.
Abstract
PURPOSE OF REVIEW: To deeply investigate one type of intracellular cardiac storage disease, the Fabry disease and one example of extracellular cardiac storage disease, the cardiac amyloidosis, with the aim to collect data about cardiac treatment at the end-stage level and the feasibility of heart transplantation (HTx) in this setting of patients. RECENT FINDINGS: Some registry describes that Fabry disease and cardiac amyloidosis showed similar characteristics as hypertrophic cardiomyopathies; thus, their correct diagnosis is often missing or time consuming. A multiorgan approach is mandatory to recognize the main systemic findings of these diseases, involving also the kidneys, the brain, the autonomous system and the skin. SUMMARY: The early diagnosis of these diseases is required to start as soon as possible the correct therapy for the patients affected. However, the end-stage heart failure is common and HTx could be offered to selected patients, especially if affected by light chain cardiac amyloidosis, to allow to perform the autologous stem cell transplantation after the cardiac transplant. Considering the Fabry disease patients, the enzyme recombinant therapy is also mandatory after HTx to avoid potential release of the systemic disease on the donor graft.
PURPOSE OF REVIEW: To deeply investigate one type of intracellular cardiac storage disease, the Fabry disease and one example of extracellular cardiac storage disease, the cardiac amyloidosis, with the aim to collect data about cardiac treatment at the end-stage level and the feasibility of heart transplantation (HTx) in this setting of patients. RECENT FINDINGS: Some registry describes that Fabry disease and cardiac amyloidosis showed similar characteristics as hypertrophic cardiomyopathies; thus, their correct diagnosis is often missing or time consuming. A multiorgan approach is mandatory to recognize the main systemic findings of these diseases, involving also the kidneys, the brain, the autonomous system and the skin. SUMMARY: The early diagnosis of these diseases is required to start as soon as possible the correct therapy for the patients affected. However, the end-stage heart failure is common and HTx could be offered to selected patients, especially if affected by light chain cardiac amyloidosis, to allow to perform the autologous stem cell transplantation after the cardiac transplant. Considering the Fabry diseasepatients, the enzyme recombinant therapy is also mandatory after HTx to avoid potential release of the systemic disease on the donor graft.
Authors: Abdelrahman N Emara; Noha O Mansour; Mohamed Hassan Elnaem; Moheb Wadie; Inderpal Singh Dehele; Mohamed E E Shams Journal: J Clin Med Date: 2022-05-31 Impact factor: 4.964
Authors: Jaimin R Trivedi; Siddharth V Pahwa; Katherine R Whitehouse; Bradley M Ceremuga; Mark S Slaughter Journal: PLoS One Date: 2022-01-26 Impact factor: 3.240
Authors: Bernhard Rauch; Annett Salzwedel; Birna Bjarnason-Wehrens; Christian Albus; Karin Meng; Jean-Paul Schmid; Werner Benzer; Matthes Hackbusch; Katrin Jensen; Bernhard Schwaab; Johann Altenberger; Nicola Benjamin; Kurt Bestehorn; Christa Bongarth; Gesine Dörr; Sarah Eichler; Hans-Peter Einwang; Johannes Falk; Johannes Glatz; Stephan Gielen; Maurizio Grilli; Ekkehard Grünig; Manju Guha; Matthias Hermann; Eike Hoberg; Stefan Höfer; Harald Kaemmerer; Karl-Heinz Ladwig; Wolfgang Mayer-Berger; Maria-Inti Metzendorf; Roland Nebel; Rhoia Clara Neidenbach; Josef Niebauer; Uwe Nixdorff; Renate Oberhoffer; Rona Reibis; Nils Reiss; Daniel Saure; Axel Schlitt; Heinz Völler; Roland von Känel; Susanne Weinbrenner; Ronja Westphal Journal: J Clin Med Date: 2021-05-19 Impact factor: 4.241